Stoke Therapeutics (STOK) Interest Coverage Ratio (2020 - 2026)
Stoke Therapeutics' (STOK) quarterly Interest Coverage Ratio came in at 2322.52 in Q1 2026, down 102.09% year-on-year from 111240.0 in Q1 2025, and down 4035.55% quarter-over-quarter from 56.16 in Q4 2025.
Stoke Therapeutics (STOK) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Stoke Therapeutics' Interest Coverage Ratio history runs 7 years deep, the most recent figure standing at 2322.52 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio fell 102.09% year-over-year to 2322.52 in Q1 2026; TTM through Mar 2026 was 165.25, a 436.62% decrease from a year earlier, with the FY2025 full-year figure at 0.11, up 97.75% from the prior year.
- Interest Coverage Ratio fell to 2322.52 in Q1 2026 per STOK's latest filing, from 56.16 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 111240.0 in Q1 2025 and bottomed at 14363.67 in Q3 2025.
- The 5-year median for Interest Coverage Ratio is 26.96 (2022), against an average of 5440.8.
- Across the five-year window, Interest Coverage Ratio plunged 71336.33% in 2024 and soared 8725.69% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.28 in 2022, then gained by 20.05% to 0.22 in 2023, then sank by 7858.15% to 17.66 in 2024, then tumbled by 217.96% to 56.16 in 2025, then slumped by 4035.55% to 2322.52 in 2026.
- Per Business Quant, the three latest STOK Interest Coverage Ratio figures stand at 2322.52 (Q1 2026), 56.16 (Q4 2025), and 14363.67 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -2,322.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,322.52 |
| Dec 31, 2025 | -56.16 |
| Sep 30, 2025 | -14,363.67 |
| Jun 30, 2025 | -4.69 |
| Mar 31, 2025 | 111,240.00 |
| Dec 31, 2024 | -17.66 |
| Jun 30, 2024 | -5,868.40 |
| Mar 31, 2024 | -1,289.64 |
| Dec 31, 2023 | -0.22 |
| Sep 30, 2023 | -158.34 |
| Jun 30, 2023 | -8.21 |
| Mar 31, 2023 | -41.29 |
| Dec 31, 2022 | -0.28 |
| Sep 30, 2022 | -15.94 |
| Jun 30, 2022 | -3.97 |
| Mar 31, 2022 | -36.25 |
| Dec 31, 2021 | -0.38 |
| Sep 30, 2021 | -8.70 |
| Jun 30, 2021 | -43.03 |
| Mar 31, 2021 | -801.29 |